Euclises Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Later Stage VC
- Investors
-
11
Euclises General Information
Description
Developer of small-molecule immunometabolic drug candidates intended for use in oncology and inflammatory diseases. The company's platform focuses on developing novel inhibitors for use in the oncology setting, as well as creating a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary platform, enabling physicians to access advanced new molecules in combinations with both immune checkpoint and EGFR inhibitors to treat cancer.
Contact Information
Website
www.euclises.comCorporate Office
- BioGenerator Accelerator Labs
- 4340 Duncan Avenue, Suite 240
- Saint Louis, MO 63110
- United States
Corporate Office
- BioGenerator Accelerator Labs
- 4340 Duncan Avenue, Suite 240
- Saint Louis, MO 63110
- United States
Euclises Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | Completed | Generating Revenue | ||||
| 6. Secondary Transaction - Private | 01-Aug-2020 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 24-Apr-2018 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 06-Jan-2017 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 07-Apr-2015 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 01-Jan-2015 | $600K | $775K | Completed | Generating Revenue | |
| 1. Early Stage VC | 16-May-2012 | $175K | $175K | Completed | Generating Revenue |
Euclises Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Euclises Comparisons
Industry
Financing
Details
Euclises Competitors (12)
One of Euclises’s 12 competitors is Lisata Therapeutics, a Corporation company based in Basking Ridge, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Adastra Pharmaceuticals | Formerly VC-backed | San Mateo, CA |
Euclises Patents
Euclises Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2017206108-A1 | Combination of a chromene compound and a second active agent | Active | 08-Jan-2016 | ||
| AU-2017206108-B2 | Combination of a chromene compound and a second active agent | Active | 08-Jan-2016 | ||
| CA-3010848-A1 | Combination of a chromene compound and a second active agent | Active | 08-Jan-2016 | ||
| EP-3400218-A1 | Combination of a chromene compound and a second active agent | Inactive | 08-Jan-2016 | ||
| EP-3400218-A4 | Combination of a chromene compound and a second active agent | Inactive | 08-Jan-2016 | A61K31/352 |
Euclises Signals
Euclises Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Argonautic Ventures | Venture Capital | Minority | ||
| iSelect Fund | Venture Capital | Minority | ||
| Lagomaj Capital | Venture Capital | Minority | ||
| ABC Laboratories | PE-Backed Company | Minority | ||
| BioGenerator Ventures | Venture Capital | Minority |
Euclises FAQs
-
When was Euclises founded?
Euclises was founded in 2011.
-
Where is Euclises headquartered?
Euclises is headquartered in Saint Louis, MO.
-
What is the size of Euclises?
Euclises has 2 total employees.
-
What industry is Euclises in?
Euclises’s primary industry is Drug Discovery.
-
Is Euclises a private or public company?
Euclises is a Private company.
-
What is Euclises’s current revenue?
The current revenue for Euclises is .
-
How much funding has Euclises raised over time?
Euclises has raised $7.38M.
-
Who are Euclises’s investors?
Argonautic Ventures, iSelect Fund, Lagomaj Capital, ABC Laboratories, and BioGenerator Ventures are 5 of 11 investors who have invested in Euclises.
-
Who are Euclises’s competitors?
Lisata Therapeutics, AnTolRx, Altimmune, Inovio Pharmaceuticals, and Adastra Pharmaceuticals are some of the 12 competitors of Euclises.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process